Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening.

Published bySanaz Gonca Ağçay Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening."— Presentation transcript:

1 Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September 2017. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact International Health, ihy096, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Diagnostic and screening cascade for hepatitis C, with positivity rate at each diagnostic step, at the MSF ... Figure 2. Diagnostic and screening cascade for hepatitis C, with positivity rate at each diagnostic step, at the MSF Clinic, Karachi, Pakistan, March 2016–September (a) Diagnostic and screening cascade for hepatitis C, with positivity rate at each diagnostic step, for patients diagnosed using RDT APRI >1. (b) Diagnostic and screening cascade for hepatitis C, with positivity rate at each diagnostic step, for patients diagnosed using RDT APRI >0.5. (c) Diagnostic and screening cascade for hepatitis C, with positivity rate at each diagnostic step, for patients diagnosed using GeneXpert. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact International Health, ihy096, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Number and proportion of patients testing seropositive for hepatitis C, by risk group category, at the MSF ... Figure 3. Number and proportion of patients testing seropositive for hepatitis C, by risk group category, at the MSF clinic, Karachi, Pakistan, March 2016–September 2017. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact International Health, ihy096, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4. Disease staging for CHC infection, by risk category, at the MSF clinic, Karachi, Pakistan, March ... Figure 4. Disease staging for CHC infection, by risk category, at the MSF clinic, Karachi, Pakistan, March 2016–September 2017. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact International Health, ihy096, The content of this slide may be subject to copyright: please see the slide notes for details.

5 Figure 5. Time interval in days between each step of the hepatitis C diagnostic and screening cascade at the MSF ... Figure 5. Time interval in days between each step of the hepatitis C diagnostic and screening cascade at the MSF clinic, Karachi, Pakistan, March 2016–September 2017. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact International Health, ihy096, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening."

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.

Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.
Figure 2. Chronic kidney disease risk tool application.

Figure 2. Chronic kidney disease risk tool application.
Fig 1 The CONSORT participant flow diagram for primary endpoints.

Fig 1 The CONSORT participant flow diagram for primary endpoints.
Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.

Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.
From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
From: Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant In vitro Susceptibilities: Risk factors and Taxon-level.

From: Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant In vitro Susceptibilities: Risk factors and Taxon-level.
From: Detection of Bacteriuria by Canine Olfaction

From: Detection of Bacteriuria by Canine Olfaction
Figure 1: (A, frontal) and (B, lateral) Final result, 4 months post-operative, after right breast reconstruction using combined TRAM flap and LDMF. From:

Figure 1: (A, frontal) and (B, lateral) Final result, 4 months post-operative, after right breast reconstruction using combined TRAM flap and LDMF. From:
Figure 3: Full-body skeletal scintigraphy.

Figure 3: Full-body skeletal scintigraphy.
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Source:Zimnisky (2014). From: An Autopsy of Cooperation: Diamond Dealers and the Limits of Trust-Based Exchange Journal of Legal Analysis. Published online.

Source:Zimnisky (2014). From: An Autopsy of Cooperation: Diamond Dealers and the Limits of Trust-Based Exchange Journal of Legal Analysis. Published online.
Figure 1. Study population diagram

Figure 1. Study population diagram
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
FIGURE 1 Kidney biopsies of Patients 1 and 2

FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2

Similar presentations

Ads by Google